Aerie Pharmaceuticals to Present at Two Upcoming Investor Conferences
June 11 2019 - 7:30AM
Business Wire
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
patients with open-angle glaucoma, retinal diseases and other
diseases of the eye today announced that Richard Rubino, Chief
Financial Officer, will present an Aerie overview and provide a
business update at two upcoming investor conferences:
- Raymond James Life Sciences and MedTech
Conference
- Date: Tuesday, June 18, 2019
- Time: 9:45 a.m. ET
- Location: New York, NY
- Presentation Format: Corporate
Presentation
- JMP Securities Life Sciences Conference
- Date: Wednesday, June 19, 2019
- Time: 3:00 p.m. ET
- Location: New York, NY
- Presentation Format: Fireside
Discussion
The presentation and fireside discussion will both be webcast
live and may be accessed by visiting Aerie’s website at
http://investors.aeriepharma.com. A replay of each webcast will be
available for 10 business days.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the
discovery, development and commercialization
of first-in-class therapies for the treatment of patients
with open-angle glaucoma, retinal diseases and other diseases of
the eye. Aerie’s first product, Rhopressa® (netarsudil
ophthalmic solution) 0.02%, a once-daily eye drop approved by
the U.S. Food and Drug Administration (FDA) for the
reduction of elevated intraocular pressure (IOP) in patients with
open-angle glaucoma or ocular hypertension, was launched
in the United States in April 2018. In clinical
trials of Rhopressa®, the most common adverse reactions were
conjunctival hyperemia, corneal verticillata, instillation site
pain, and conjunctival hemorrhage. More information about
Rhopressa®, including the product label, is available
at www.rhopressa.com. Aerie’s second product for the reduction
of elevated IOP in patients with open-angle glaucoma or ocular
hypertension, Rocklatan® (netarsudil and latanoprost
ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose
combination of Rhopressa® and the
widely-prescribed PGA (prostaglandin analog) latanoprost,
has been approved by the FDA and was launched
in the United States in the second quarter of 2019.
In clinical trials of Rocklatan®, the most common adverse
reactions were conjunctival hyperemia, corneal verticillata,
instillation site pain, and conjunctival hemorrhage. More
information about Rocklatan®, including the product label, is
available at www.rocklatan.com. Aerie continues to focus on
global expansion and the development of additional product
candidates and technologies in ophthalmology, including for
wet age-related macular degeneration and diabetic macular
edema. More information is available
at www.aeriepharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190611005016/en/
Media: Tad Heitmann 949-526-8747;
theitmann@aeriepharma.comInvestors: Ami Bavishi 908-947-3949;
abavishi@aeriepharma.com
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Sep 2023 to Sep 2024